Eloralintide Peptide: The Amylin Drug and Its Trial Data
Eloralintide peptide (code LY3841136) is an investigational once weekly amylin receptor drug with no FDA label. In a published 48 week phase 2 trial of 263 adults, average body weight fell by up to 20% against 0.4% on placebo, and ClinicalTrials.gov now lists phase 3 trials.
Sources: Phase 2 trial, PubMed 41207310; NCT07321886
Short answer
- What is eloralintide?
- A lab-made drug that acts on amylin receptors, built to be injected once a week. It is still in trials.
- What did the main trial find?
- After 48 weeks, weight was about 16% to 20% lower in the higher dose groups, against 0.4% on placebo. Nausea and fatigue were the most common side effects.
- Can you get it?
- Not as an approved medicine. There is no FDA label. Phase 3 trials such as NCT07321886 are listed on ClinicalTrials.gov.
Sources: Phase 2 trial, PubMed 41207310; Discovery paper full text, PMC12640043; NCT07321886
How Does Eloralintide Work?
Eloralintide copies the action of amylin, a natural hormone. Amylin is released together with insulin from beta cells in the pancreas. It slows how fast the stomach empties, lowers the hormone glucagon and helps the brain end a meal.
Amylin acts on more than one receptor. In lab cells, eloralintide switched on the human AMY1 receptor 12 times more than the calcitonin receptor and 11 times more than the AMY3 receptor. That is why reviews call it a selective AMY1 receptor drug.
Natural amylin does not last long in the body. Eloralintide carries a C20 fatty diacid chain joined at the lysine in position 26. That chain lets it bind albumin, a protein in the blood, which stretches its action enough for one shot a week.
Before people, it was tested in rats made obese by diet. In those rats it cut food intake and lowered body weight, mostly through fat loss, and more so at higher doses. That is animal data, and it was the base for the human trials below.
Sources: Amylin review, PubMed 42452898; Discovery paper, PubMed 41109426; Discovery paper full text, PMC12640043
The 48 Week Phase 2 Trial
The phase 2 trial is the largest eloralintide study published so far. It enrolled 263 people from 46 research centres in the USA and ran for 48 weeks. Neither the people nor the researchers knew who got the drug and who got placebo.
People were split into seven groups in a 2:1:1:1:2:1:2 ratio. Some got placebo. The rest got one of four fixed doses or one of two stepped up schedules, all as a shot under the skin once a week.
The phase 2 trial report (The Lancet, PubMed 41207310) lists these weekly injection arms:
1 mg, 3 mg, 6 mg or 9 mg once weekly
Stepped up from 6 to 9 mg, or from 3 to 9 mg
Placebo once weekly
Disclaimer: these are research trial doses, not label information and not a recommendation. Eloralintide has no approved dose. Dose decisions belong with a licensed clinician.
The trial was run by a team that includes Eli Lilly staff. The paper states that seven of its authors are employees and stockholders of Eli Lilly and Company. Keep that link in mind when you read the results.
Sources: Phase 2 trial, PubMed 41207310
Eloralintide Results and Side Effects by Dose
Higher doses brought more weight loss, and the side effects did not rise in a straight line. The table puts weight change, nausea and fatigue for each phase 2 group side by side, so you can see the trade off in one place.
| Group | Average weight change | Nausea | Fatigue |
|---|---|---|---|
| Placebo | 0.4% down | 14% | 12% |
| 1 mg weekly injection | About 9% down | 11% | 0% |
| 3 mg weekly injection | About 12% down | 13% | 13% |
| 6 mg weekly injection | About 18% down | 64% | 29% |
| 9 mg weekly injection | About 20% down | 33% | 43% |
| Stepped up, 6 to 9 mg | About 20% down | 54% | 46% |
| Stepped up, 3 to 9 mg | About 16% down | 25% | 21% |
Disclaimer: the doses in this table are trial arms, not a recommendation. Dose decisions belong with a licensed clinician.
What the table shows
Three things stand out. First, the 9 mg group and the 6 to 9 mg group both reached about 20% average weight loss. Second, nausea was highest in the fixed 6 mg group at 64%, higher than in the 9 mg group at 33%. Third, fatigue was common at the top doses, at 43% on 9 mg and 46% on the 6 to 9 mg schedule.
The two stepped up groups started lower and moved to 9 mg. The 3 to 9 mg group had less nausea (25%) and less fatigue (21%) than the fixed 9 mg group, and a smaller average weight loss of about 16%.
Sources: Phase 2 trial, PubMed 41207310
The Phase 1 Studies
Two phase 1 studies came first. They were small and short, and their main job was to check safety.
The first (NCT05295940) gave a single shot to healthy adults, with doses from 0.04 to 12 mg, against placebo. It looked at safety and how well people tolerated it.
The second gave repeated doses to 100 people in five rising dose groups. They had a mean age of 44, 29% were women, and their mean BMI was 32.6. At week 12, average weight loss across the dose groups ranged from 2.6% to 11.3%. There were no deaths. One serious adverse event occurred in an eloralintide group (6 mg), and it was judged unrelated to eloralintide.
Sources: Discovery paper, PubMed 41109426; Phase 1 multiple dose study, PubMed 41559929
What Are the Common Side Effects of Eloralintide?
Nausea and fatigue were the most common side effects in the phase 2 trial. In the phase 1 repeated dose study, the most common were decreased appetite (19%), headache (12%), fatigue (11%) and COVID-19 (11%).
Stomach side effects looked different in the two studies. In phase 1, the authors called them infrequent: diarrhoea in 10%, nausea in 8% and vomiting in 4%. In phase 2, which ran much longer, nausea reached 64% in one group.
A 2026 review says early evidence links eloralintide to a distinct side effect pattern, including fatigue, headache and appetite loss. A separate 2026 review notes that no amylin receptor drug, eloralintide included, has been through a dedicated cardiovascular outcomes trial. So it has not yet been through a trial built to measure long term heart outcomes.
For the side effect picture of the GLP-1 drugs people often compare it with, see our GLP-1 side effects guide.
Sources: Phase 2 trial, PubMed 41207310; Phase 1 multiple dose study, PubMed 41559929; Amylin agonist review, PubMed 42803913; Heart review, PubMed 42745233
Is Eloralintide Approved? Phase 3 Status
Eloralintide is not approved. openFDA has no label for it, and ClinicalTrials.gov lists phase 3 trials as recruiting. So it is past phase 2, but still being tested.
The timeline below lists each eloralintide study in this guide, from the first single dose test to the phase 3 trials.
| Study | Stage | Who | What it tests |
|---|---|---|---|
| NCT05295940 | Phase 1, single dose | Healthy adults | Safety and tolerability of one dose, from 0.04 to 12 mg |
| Phase 1, multiple dose | Phase 1 | 100 adults, mean BMI 32.6 | Five rising dose groups against placebo, weight at week 12 |
| Phase 2 (PubMed 41207310) | Phase 2, published | 263 adults at 46 US centres | Weekly shots for 48 weeks against placebo |
| NCT06916065 | Registered study | Overweight or obesity | Tolerability alone and with tirzepatide |
| NCT07321886 | Phase 3 | Obesity, or overweight without type 2 diabetes | Randomized, double masked, 1980 people estimated |
| NCT07282600 | Registered trial | Overweight or obesity with type 2 diabetes | Weight reduction against placebo |
NCT07321886 is the largest. Its record lists it as phase 3, randomized and double masked, with 1980 people planned who have obesity, or overweight without type 2 diabetes. NCT07282600 compares eloralintide with placebo for weight reduction in people with overweight or obesity and type 2 diabetes.
A third registered study, NCT06916065, looks at how well eloralintide is tolerated alone and together with tirzepatide, and what side effects occur. For how a weight loss drug moves from late trials toward approval, see our guide on when retatrutide will be available.
Sources: NCT07321886; NCT07282600; NCT06916065
Where Can You Buy Eloralintide Peptide?
No approved eloralintide product exists to buy. With no FDA label, the only official records of people receiving it are the trials listed above.
Powders sold online under the name are not the product used in those trials, and no official record confirms what they contain or how pure they are. Our guide to reading a certificate of analysis explains what a lab report can and cannot show.
Sources: NCT07321886; NCT07282600
Common Questions
What are the common side effects of taking Eloralintide peptide?+
In the 48 week phase 2 trial, the most common side effects were nausea and fatigue. Nausea ran from 11% to 64% across the dose groups against 14% on placebo, and fatigue from 0% to 46% against 12% on placebo. In a smaller phase 1 study, the most common were decreased appetite (19%), headache (12%), fatigue (11%) and COVID-19 (11%).
Where can I buy Eloralintide peptide?+
There is no approved product to buy. Eloralintide is an investigational drug with no FDA label, and the official records describe it only inside clinical trials. Anything sold online under that name is not the product tested in those trials, and nothing confirms what it contains.
Is eloralintide FDA approved?+
No. openFDA has no label for eloralintide, so there is no approved product. ClinicalTrials.gov lists phase 3 trials, such as NCT07321886, which shows it is still being studied.
How much weight did people lose on eloralintide?+
In the phase 2 trial, average weight after 48 weeks was about 18% lower on 6 mg, 20% lower on 9 mg, 20% lower on a 6 to 9 mg schedule and 16% lower on a 3 to 9 mg schedule. The placebo group was 0.4% lower. These are trial doses, not a recommendation; dose decisions belong with a licensed clinician.
How does eloralintide work?+
It mimics amylin, a hormone released with insulin that slows stomach emptying, lowers glucagon and helps end a meal. In lab cells it switched on the AMY1 amylin receptor 12 times more than the calcitonin receptor and 11 times more than the AMY3 receptor.
Is eloralintide a weekly shot?+
Yes, in the trials. A fatty diacid chain on the molecule binds albumin in the blood, which lengthens its action for once weekly dosing. The phase 2 trial gave it as a once weekly injection under the skin.
Is eloralintide the same as a GLP-1 drug?+
No. Eloralintide targets amylin receptors, not the GLP-1 receptor. A 2026 review says early evidence ties it to a distinct side effect pattern, including fatigue, headache and appetite loss. One registered study tests it together with tirzepatide.
Sources: Phase 2 trial, PubMed 41207310; Phase 1 multiple dose study, PubMed 41559929; Discovery paper full text, PMC12640043; Amylin review, PubMed 42452898; Amylin agonist review, PubMed 42803913; NCT07321886
Related reading
This guide is for educational purposes only and is not medical advice. It describes what published trials, reviews and trial registry records report about eloralintide. Eloralintide is an investigational drug that is not approved for any use. Talk to a qualified healthcare professional before making any decision about your health.